Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 63186-63187 [2016-22058]
Download as PDF
<![CDATA[
63186
Federal Register / Vol. 81, No. 178 / Wednesday, September 14, 2016 / Notices
consider all timely and responsive
public comments that it receives on or
before [30 days from Federal Register
date of publication]. For information on
the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/ftc/
privacy.htm.
David C. Shonka,
Acting General Counsel.
[FR Doc. 2016–22106 Filed 9–13–16; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Safety and Occupational Health Study
Section (SOHSS), National Institute for
Occupational Safety and Health
(NIOSH or Institute)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
Times and Dates: 8:00 a.m.–5:00 p.m.,
EDT, October 11, 2016 (Closed); 8:00
a.m.–5:00 p.m., EDT, October 12, 2016
(Closed).
Place: Embassy Suites, 1900 Diagonal
Road, Alexandria, Virginia 22314,
Telephone: 703–684–5900, Fax: 703–
684–0653.
Purpose: The Safety and Occupational
Health Study Section will review,
discuss, and evaluate grant
application(s) received in response to
the Institute’s standard grants review
and funding cycles pertaining to
research issues in occupational safety
and health, and allied areas.
It is the intent of NIOSH to support
broad-based research endeavors in
keeping with the Institute’s program
goals. This will lead to improved
understanding and appreciation for the
magnitude of the aggregate health
burden associated with occupational
injuries and illnesses, as well as to
support more focused research projects,
which will lead to improvements in the
delivery of occupational safety and
health services, and the prevention of
work-related injury and illness. It is
anticipated that research funded will
promote these program goals.
Matters for Discussion: The meeting
will convene to address matters related
to the conduct of Study Section
business and for the study section to
consider safety and occupational healthrelated grant applications.
VerDate Sep<11>2014
20:55 Sep 13, 2016
Jkt 238001
These portions of the meeting will be
closed to the public in accordance with
provisions set forth in section 552b(c)(4)
and (6), title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, Centers for Disease Control and
Prevention, pursuant to section 10(d)
Public Law 92–463.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Joanne Fairbanks, Designated Federal
Officer, NIOSH, CDC, 1095 Willowdale
Road, Morgantown, WV 26506, Mailstop
L1119, Telephone: (304) 285–6143.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–22059 Filed 9–13–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC) announces the
following committee meeting:
Time and Date: 11:00 a.m.–2:00 p.m.,
EDT, October 4, 2016.
Place: Audio Conference Call via FTS
Conferencing.
Status: Open to the public. The public
is welcome to submit written comments
in advance of the meeting, to the contact
person below. Written comments
received in advance of the meeting will
be included in the official record of the
meeting. The public is also welcome to
listen to the meeting by joining the
teleconference at the USA toll-free, dialin number, 1–866–659–0537, passcode
9933701.
Background: The Advisory Board was
established under the Energy Employees
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines,
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
intervals, rechartered on March 22, 2016
pursuant to Executive Order 13708, and
will expire on September 30, 2017.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters for Discussion: The agenda for
the conference call includes: Final
Special Exposure Cohort (SEC) Petition
Votes from August ABRWH Meeting for
Blockson Chemical Co. (Joliet, Illinois)
and Westinghouse Electric Co.
(Bloomfield, New Jersey); Bliss and
Laughlin Steel SEC Petition (Buffalo,
New York), Work Group and
Subcommittee Reports; SEC Petitions
Update for the November 2016 Advisory
Board Meeting; Plans for the November
2016 Advisory Board Meeting; and
Advisory Board Correspondence.
Contact Person for More Information:
Theodore M. Katz, M.P.A., Designated
Federal Officer, NIOSH, CDC, 1600
Clifton Road NE., Mailstop: E–20,
Atlanta, Georgia 30333, Telephone (513)
E:\FR\FM\14SEN1.SGM
14SEN1
Federal Register / Vol. 81, No. 178 / Wednesday, September 14, 2016 / Notices
533–6800, Toll Free 1–800–CDC–INFO,
Email ocas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–22058 Filed 9–13–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–D–2635]
The Judicious Use of Medically
Important Antimicrobial Drugs in FoodProducing Animals; Establishing
Appropriate Durations of Therapeutic
Administration; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; request for comments.
The Food and Drug
Administration (FDA, the Agency, we)
is soliciting comments regarding the
establishment of appropriately targeted
durations of use of antimicrobial drugs
of importance to human medicine (i.e.,
medically important antimicrobial
drugs) when they are administered in
the feed or water of food-producing
animals for therapeutic purposes. This
activity is consistent with previous
efforts by FDA to protect public health
by promoting the judicious use of these
drugs in food-producing animals.
DATES: Submit either electronic or
written comments by December 13,
2016.
SUMMARY:
ADDRESSES:
You may submit comments
as follows:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
VerDate Sep<11>2014
20:55 Sep 13, 2016
Jkt 238001
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–D–2635 for ‘‘Establishing
Appropriate Durations of Therapeutic
Administration.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
63187
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Cindy Burnsteel, Center for Veterinary
Medicine (HFV–130), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–0817,
cindy.burnsteel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On September 18, 2014, the President
issued Executive Order 13676 on
‘‘Combating Antibiotic-Resistant
Bacteria’’ (https://www.gpo.gov/fdsys/
pkg/FR-2014-09-23/pdf/201422805.pdf), underscoring the urgent
need to address the global threat of
antimicrobial resistance. The National
Action Plan for Combating AntibioticResistant Bacteria (National Action
Plan) (March 2015, https://
www.whitehouse.gov/sites/default/files/
docs/national_action_plan_for_
combating_antibotic-resistant_
bacteria.pdf) was developed in response
to this Executive order, and presents a
strategy for collaborative action by the
U.S. Government in coordination with
individuals and organizations within
the human and animal health sectors.
The plan establishes specific goals and
objectives within a 5-year timeframe,
outlines steps for implementing certain
measures, and informs national policy
development in order to combat the
emergence of antimicrobial-resistant
bacteria.
FDA is actively engaged in several
ongoing efforts to address antimicrobial
resistance originating from the use of
antimicrobial drugs that are important
in human medicine (medically
important antimicrobials) in food-
E:\FR\FM\14SEN1.SGM
14SEN1
]]>Agencies
[Federal Register Volume 81, Number 178 (Wednesday, September 14, 2016)]
[Notices]
[Pages 63186-63187]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-22058]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or the
Advisory Board), National Institute for Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42
CFR 83.15(a), the Centers for Disease Control and Prevention (CDC)
announces the following committee meeting:
Time and Date: 11:00 a.m.-2:00 p.m., EDT, October 4, 2016.
Place: Audio Conference Call via FTS Conferencing.
Status: Open to the public. The public is welcome to submit written
comments in advance of the meeting, to the contact person below.
Written comments received in advance of the meeting will be included in
the official record of the meeting. The public is also welcome to
listen to the meeting by joining the teleconference at the USA toll-
free, dial-in number, 1-866-659-0537, passcode 9933701.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines, which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule; advice on methods of dose reconstruction, which have
also been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, rechartered on March 22, 2016
pursuant to Executive Order 13708, and will expire on September 30,
2017.
Purpose: This Advisory Board is charged with (a) providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advising the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Matters for Discussion: The agenda for the conference call
includes: Final Special Exposure Cohort (SEC) Petition Votes from
August ABRWH Meeting for Blockson Chemical Co. (Joliet, Illinois) and
Westinghouse Electric Co. (Bloomfield, New Jersey); Bliss and Laughlin
Steel SEC Petition (Buffalo, New York), Work Group and Subcommittee
Reports; SEC Petitions Update for the November 2016 Advisory Board
Meeting; Plans for the November 2016 Advisory Board Meeting; and
Advisory Board Correspondence.
Contact Person for More Information: Theodore M. Katz, M.P.A.,
Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road NE.,
Mailstop: E-20, Atlanta, Georgia 30333, Telephone (513)
[[Page 63187]]
533-6800, Toll Free 1-800-CDC-INFO, Email ocas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-22058 Filed 9-13-16; 8:45 am]
BILLING CODE 4163-18-P
